There is presently no treatment specifically approved to halt the neurological damage that continues for hours and days in the wake of a brain injury. But there is an already-approved compound that some scientists and clinicians believe will prove helpful. The backers of NeuroPharma are betting that a new formulation of cyclosporin, the drug long used to prevent rejection of transplanted organs, can be shown to have a beneficial effect on people with TBI.
Magle Stora Kyrkogata 6
S-223 50 Lund, Sweden
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
Deal Snapshot: Having recently raised an $89m IPO, BioVersys is partnering on and optioning rights to a preclinical NTM development program with Shionogi.
Deal Snapshot: The French drugmaker has been shifting its investments away from cancer to focus on immunology and inflammation but it continues to seek out interesting early-stage oncology assets.